A significant subgroup of resectable gallbladder cancer patients has an HER2 positive status

Gallbladder cancer (GBC) has a poor prognosis, and new targeted therapeutic options are needed. We investigated the human epidermal growth factor receptor 2 (HER2) status and its clinicopathological significance in a large cohort of GBC patients. We assessed HER2 expression in a consecutive series o...

Full description

Saved in:
Bibliographic Details
Published in:Virchows Archiv : an international journal of pathology 2016-04, Vol.468 (4), p.431-439
Main Authors: Yoshida, Hiroshi, Shimada, Kazuaki, Kosuge, Tomoo, Hiraoka, Nobuyoshi
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor - analysis
Carcinoma - genetics
Carcinoma - pathology
Female
Gallbladder Neoplasms - genetics
Gallbladder Neoplasms - pathology
Gene Amplification
Heterogeneity
Humans
Immunohistochemistry
In Situ Hybridization, Fluorescence
Male
Medicine
Medicine & Public Health
Middle Aged
Original Article
Pathology
Receptor, ErbB-2 - analysis
Receptor, ErbB-2 - biosynthesis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c438t-33fd25564b9bad8ff4716c6eea8f163b70b5618354f20c30a7870813406208c3
cites cdi_FETCH-LOGICAL-c438t-33fd25564b9bad8ff4716c6eea8f163b70b5618354f20c30a7870813406208c3
container_end_page 439
container_issue 4
container_start_page 431
container_title Virchows Archiv : an international journal of pathology
container_volume 468
creator Yoshida, Hiroshi
Shimada, Kazuaki
Kosuge, Tomoo
Hiraoka, Nobuyoshi
description Gallbladder cancer (GBC) has a poor prognosis, and new targeted therapeutic options are needed. We investigated the human epidermal growth factor receptor 2 (HER2) status and its clinicopathological significance in a large cohort of GBC patients. We assessed HER2 expression in a consecutive series of 211 GBC cases by immunohistochemistry (IHC), paying particular attention to intratumoral heterogeneity. HER2 gene amplification was analyzed by dual-color fluorescence in situ hybridization (FISH). An HER2 positive status was called when the IHC score was 3+ or when the IHC score was 2+, and FISH was positive. Correlations were analyzed between HER2 status and clinicopathological parameters including survival. The HER2 IHC score was 0 in 144 (68.2 %), 1+ in 28 (13.3 %), 2+ in 14 (6.6 %), and 3+ in 25 cases (11.8 %). In 20/39 (51 %) of the IHC 2+ and 3+ cases, the staining pattern was heterogeneous. In HER2 IHC score 2+ and 3+ cases, HER2 FISH was positive in 83 % (10/12) and 96 % (24/25), respectively. Altogether, 35/211 cases (16.6 %) were HER2 positive. There was no significant association between HER2 status and clinicopathological variables or survival. We identified a significant subgroup of HER2-positive GBC cases, for whom a clinical trial with anti-HER2 therapy might be considered.
doi_str_mv 10.1007/s00428-015-1898-1
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1781537707</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1781537707</sourcerecordid><originalsourceid>FETCH-LOGICAL-c438t-33fd25564b9bad8ff4716c6eea8f163b70b5618354f20c30a7870813406208c3</originalsourceid><addsrcrecordid>eNp1kE1rFEEQhhtRzCbxB3iRBi9eRqv6e48hRCMEAiHHQNPT071OmJ0Zu3oE_31m2RhE8FSHet63ioex9wifEcB-IQAlXAOoG3Rb1-ArtkElRSMk2NdsA1ulGyPRnrBTokcAgQ7NW3YijNUOtNuwhwtO_W7scx_DWDkt7a5My8ynzEuiFGtoh8R3YRjaIXRdKnzl4jrmUPs0VuI_AvEw8uurO8Hnifra_0qcaqgLnbM3OQyU3j3PM3b_9er-8rq5uf32_fLipolKutpImTuhtVHttg2dy1lZNNGkFFxGI1sLrTbopFZZQJQQrLPgUCowAlyUZ-zTsXYu088lUfX7nmIahjCmaSGP1qGW1oJd0Y__oI_TUsb1uQMFVklAXCk8UrFMRCVlP5d-H8pvj-AP5v3RvF_N-4N5f8h8eG5e2n3qXhJ_VK-AOAK0rsZdKn-d_m_rE9APjLQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1780743011</pqid></control><display><type>article</type><title>A significant subgroup of resectable gallbladder cancer patients has an HER2 positive status</title><source>Springer Nature</source><creator>Yoshida, Hiroshi ; Shimada, Kazuaki ; Kosuge, Tomoo ; Hiraoka, Nobuyoshi</creator><creatorcontrib>Yoshida, Hiroshi ; Shimada, Kazuaki ; Kosuge, Tomoo ; Hiraoka, Nobuyoshi</creatorcontrib><description>Gallbladder cancer (GBC) has a poor prognosis, and new targeted therapeutic options are needed. We investigated the human epidermal growth factor receptor 2 (HER2) status and its clinicopathological significance in a large cohort of GBC patients. We assessed HER2 expression in a consecutive series of 211 GBC cases by immunohistochemistry (IHC), paying particular attention to intratumoral heterogeneity. HER2 gene amplification was analyzed by dual-color fluorescence in situ hybridization (FISH). An HER2 positive status was called when the IHC score was 3+ or when the IHC score was 2+, and FISH was positive. Correlations were analyzed between HER2 status and clinicopathological parameters including survival. The HER2 IHC score was 0 in 144 (68.2 %), 1+ in 28 (13.3 %), 2+ in 14 (6.6 %), and 3+ in 25 cases (11.8 %). In 20/39 (51 %) of the IHC 2+ and 3+ cases, the staining pattern was heterogeneous. In HER2 IHC score 2+ and 3+ cases, HER2 FISH was positive in 83 % (10/12) and 96 % (24/25), respectively. Altogether, 35/211 cases (16.6 %) were HER2 positive. There was no significant association between HER2 status and clinicopathological variables or survival. We identified a significant subgroup of HER2-positive GBC cases, for whom a clinical trial with anti-HER2 therapy might be considered.</description><identifier>ISSN: 0945-6317</identifier><identifier>EISSN: 1432-2307</identifier><identifier>DOI: 10.1007/s00428-015-1898-1</identifier><identifier>PMID: 26758058</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor - analysis ; Carcinoma - genetics ; Carcinoma - pathology ; Female ; Gallbladder Neoplasms - genetics ; Gallbladder Neoplasms - pathology ; Gene Amplification ; Heterogeneity ; Humans ; Immunohistochemistry ; In Situ Hybridization, Fluorescence ; Male ; Medicine ; Medicine &amp; Public Health ; Middle Aged ; Original Article ; Pathology ; Receptor, ErbB-2 - analysis ; Receptor, ErbB-2 - biosynthesis</subject><ispartof>Virchows Archiv : an international journal of pathology, 2016-04, Vol.468 (4), p.431-439</ispartof><rights>Springer-Verlag Berlin Heidelberg 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c438t-33fd25564b9bad8ff4716c6eea8f163b70b5618354f20c30a7870813406208c3</citedby><cites>FETCH-LOGICAL-c438t-33fd25564b9bad8ff4716c6eea8f163b70b5618354f20c30a7870813406208c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26758058$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yoshida, Hiroshi</creatorcontrib><creatorcontrib>Shimada, Kazuaki</creatorcontrib><creatorcontrib>Kosuge, Tomoo</creatorcontrib><creatorcontrib>Hiraoka, Nobuyoshi</creatorcontrib><title>A significant subgroup of resectable gallbladder cancer patients has an HER2 positive status</title><title>Virchows Archiv : an international journal of pathology</title><addtitle>Virchows Arch</addtitle><addtitle>Virchows Arch</addtitle><description>Gallbladder cancer (GBC) has a poor prognosis, and new targeted therapeutic options are needed. We investigated the human epidermal growth factor receptor 2 (HER2) status and its clinicopathological significance in a large cohort of GBC patients. We assessed HER2 expression in a consecutive series of 211 GBC cases by immunohistochemistry (IHC), paying particular attention to intratumoral heterogeneity. HER2 gene amplification was analyzed by dual-color fluorescence in situ hybridization (FISH). An HER2 positive status was called when the IHC score was 3+ or when the IHC score was 2+, and FISH was positive. Correlations were analyzed between HER2 status and clinicopathological parameters including survival. The HER2 IHC score was 0 in 144 (68.2 %), 1+ in 28 (13.3 %), 2+ in 14 (6.6 %), and 3+ in 25 cases (11.8 %). In 20/39 (51 %) of the IHC 2+ and 3+ cases, the staining pattern was heterogeneous. In HER2 IHC score 2+ and 3+ cases, HER2 FISH was positive in 83 % (10/12) and 96 % (24/25), respectively. Altogether, 35/211 cases (16.6 %) were HER2 positive. There was no significant association between HER2 status and clinicopathological variables or survival. We identified a significant subgroup of HER2-positive GBC cases, for whom a clinical trial with anti-HER2 therapy might be considered.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Carcinoma - genetics</subject><subject>Carcinoma - pathology</subject><subject>Female</subject><subject>Gallbladder Neoplasms - genetics</subject><subject>Gallbladder Neoplasms - pathology</subject><subject>Gene Amplification</subject><subject>Heterogeneity</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>In Situ Hybridization, Fluorescence</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Middle Aged</subject><subject>Original Article</subject><subject>Pathology</subject><subject>Receptor, ErbB-2 - analysis</subject><subject>Receptor, ErbB-2 - biosynthesis</subject><issn>0945-6317</issn><issn>1432-2307</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNp1kE1rFEEQhhtRzCbxB3iRBi9eRqv6e48hRCMEAiHHQNPT071OmJ0Zu3oE_31m2RhE8FSHet63ioex9wifEcB-IQAlXAOoG3Rb1-ArtkElRSMk2NdsA1ulGyPRnrBTokcAgQ7NW3YijNUOtNuwhwtO_W7scx_DWDkt7a5My8ynzEuiFGtoh8R3YRjaIXRdKnzl4jrmUPs0VuI_AvEw8uurO8Hnifra_0qcaqgLnbM3OQyU3j3PM3b_9er-8rq5uf32_fLipolKutpImTuhtVHttg2dy1lZNNGkFFxGI1sLrTbopFZZQJQQrLPgUCowAlyUZ-zTsXYu088lUfX7nmIahjCmaSGP1qGW1oJd0Y__oI_TUsb1uQMFVklAXCk8UrFMRCVlP5d-H8pvj-AP5v3RvF_N-4N5f8h8eG5e2n3qXhJ_VK-AOAK0rsZdKn-d_m_rE9APjLQ</recordid><startdate>20160401</startdate><enddate>20160401</enddate><creator>Yoshida, Hiroshi</creator><creator>Shimada, Kazuaki</creator><creator>Kosuge, Tomoo</creator><creator>Hiraoka, Nobuyoshi</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7TO</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20160401</creationdate><title>A significant subgroup of resectable gallbladder cancer patients has an HER2 positive status</title><author>Yoshida, Hiroshi ; Shimada, Kazuaki ; Kosuge, Tomoo ; Hiraoka, Nobuyoshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c438t-33fd25564b9bad8ff4716c6eea8f163b70b5618354f20c30a7870813406208c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Carcinoma - genetics</topic><topic>Carcinoma - pathology</topic><topic>Female</topic><topic>Gallbladder Neoplasms - genetics</topic><topic>Gallbladder Neoplasms - pathology</topic><topic>Gene Amplification</topic><topic>Heterogeneity</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>In Situ Hybridization, Fluorescence</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Middle Aged</topic><topic>Original Article</topic><topic>Pathology</topic><topic>Receptor, ErbB-2 - analysis</topic><topic>Receptor, ErbB-2 - biosynthesis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yoshida, Hiroshi</creatorcontrib><creatorcontrib>Shimada, Kazuaki</creatorcontrib><creatorcontrib>Kosuge, Tomoo</creatorcontrib><creatorcontrib>Hiraoka, Nobuyoshi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest_Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Biological Science Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Virchows Archiv : an international journal of pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yoshida, Hiroshi</au><au>Shimada, Kazuaki</au><au>Kosuge, Tomoo</au><au>Hiraoka, Nobuyoshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A significant subgroup of resectable gallbladder cancer patients has an HER2 positive status</atitle><jtitle>Virchows Archiv : an international journal of pathology</jtitle><stitle>Virchows Arch</stitle><addtitle>Virchows Arch</addtitle><date>2016-04-01</date><risdate>2016</risdate><volume>468</volume><issue>4</issue><spage>431</spage><epage>439</epage><pages>431-439</pages><issn>0945-6317</issn><eissn>1432-2307</eissn><abstract>Gallbladder cancer (GBC) has a poor prognosis, and new targeted therapeutic options are needed. We investigated the human epidermal growth factor receptor 2 (HER2) status and its clinicopathological significance in a large cohort of GBC patients. We assessed HER2 expression in a consecutive series of 211 GBC cases by immunohistochemistry (IHC), paying particular attention to intratumoral heterogeneity. HER2 gene amplification was analyzed by dual-color fluorescence in situ hybridization (FISH). An HER2 positive status was called when the IHC score was 3+ or when the IHC score was 2+, and FISH was positive. Correlations were analyzed between HER2 status and clinicopathological parameters including survival. The HER2 IHC score was 0 in 144 (68.2 %), 1+ in 28 (13.3 %), 2+ in 14 (6.6 %), and 3+ in 25 cases (11.8 %). In 20/39 (51 %) of the IHC 2+ and 3+ cases, the staining pattern was heterogeneous. In HER2 IHC score 2+ and 3+ cases, HER2 FISH was positive in 83 % (10/12) and 96 % (24/25), respectively. Altogether, 35/211 cases (16.6 %) were HER2 positive. There was no significant association between HER2 status and clinicopathological variables or survival. We identified a significant subgroup of HER2-positive GBC cases, for whom a clinical trial with anti-HER2 therapy might be considered.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>26758058</pmid><doi>10.1007/s00428-015-1898-1</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0945-6317
ispartof Virchows Archiv : an international journal of pathology, 2016-04, Vol.468 (4), p.431-439
issn 0945-6317
1432-2307
language eng
recordid cdi_proquest_miscellaneous_1781537707
source Springer Nature
subjects Adult
Aged
Aged, 80 and over
Biomarkers, Tumor - analysis
Carcinoma - genetics
Carcinoma - pathology
Female
Gallbladder Neoplasms - genetics
Gallbladder Neoplasms - pathology
Gene Amplification
Heterogeneity
Humans
Immunohistochemistry
In Situ Hybridization, Fluorescence
Male
Medicine
Medicine & Public Health
Middle Aged
Original Article
Pathology
Receptor, ErbB-2 - analysis
Receptor, ErbB-2 - biosynthesis
title A significant subgroup of resectable gallbladder cancer patients has an HER2 positive status
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T02%3A11%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20significant%20subgroup%20of%20resectable%20gallbladder%20cancer%20patients%20has%20an%20HER2%20positive%20status&rft.jtitle=Virchows%20Archiv%20:%20an%20international%20journal%20of%20pathology&rft.au=Yoshida,%20Hiroshi&rft.date=2016-04-01&rft.volume=468&rft.issue=4&rft.spage=431&rft.epage=439&rft.pages=431-439&rft.issn=0945-6317&rft.eissn=1432-2307&rft_id=info:doi/10.1007/s00428-015-1898-1&rft_dat=%3Cproquest_cross%3E1781537707%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c438t-33fd25564b9bad8ff4716c6eea8f163b70b5618354f20c30a7870813406208c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1780743011&rft_id=info:pmid/26758058&rfr_iscdi=true